Figure 6
From: Dextran-Catechin inhibits angiogenesis by disrupting copper homeostasis in endothelial cells
Dextran-Catechin showed significant anticancer and antiangiogenic activity in neuroblastoma mouse models. Nude mice (BALB/c) injected subcutaneously with human IMR-32 cells were treated with 300 μg/ml Dextran-Catechin when the mean tumor volume reached about 200 mm3. Treatment administered i.v. weekly for three weeks significantly reduced tumor growth in mice treated with 300 μg/ml Dextran-Catechin compared to the saline control cohort. (a) Graph of tumor size changes between control and treatment group. Lines, n = 4; Bars, SEM (*p < 0.05, **p < 0.01, ***p < 0.001). (b) Representative photographs of endothelial cells stained immunohistochemically for CD31 in tumors between control and treatment. (Average number of vascular structure per image; means of at least three individual experiments) Arrows pointing at vascular structure; Scale bar 20 µM. (c) Number of vascular structures are higher in the control group compared to the Dextran-Catechin treatment group. Columns, n = 3; Bars, SEM (**P < 0.05).
